Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

Ian Chau, MD
Published: Saturday, Jan 21, 2017


Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab (Keytruda).
 
Most of the patients participating in the study were heavily pre-treated, with the majority being treated in the third-line setting. The combination of ramucirumab plus pembrolizumab was very well tolerated, Chau says, with hardly any treatment-related grade 3 toxicities observed.
 
In terms of efficacy, though there are only short-term follow-up results as of now, 4 objectives responses were observed, which represents 10% of the patients. Though it may not seem like a high percentage, Chau says, many patients demonstrated prolonged disease stabilization.
 
At this time, investigators are still waiting for mature data for progression-free survival and overall survival. Those results will help determine how to move forward with future development of the ramucirumab/pembrolizumab combination.
 

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab (Keytruda).
 
Most of the patients participating in the study were heavily pre-treated, with the majority being treated in the third-line setting. The combination of ramucirumab plus pembrolizumab was very well tolerated, Chau says, with hardly any treatment-related grade 3 toxicities observed.
 
In terms of efficacy, though there are only short-term follow-up results as of now, 4 objectives responses were observed, which represents 10% of the patients. Though it may not seem like a high percentage, Chau says, many patients demonstrated prolonged disease stabilization.
 
At this time, investigators are still waiting for mature data for progression-free survival and overall survival. Those results will help determine how to move forward with future development of the ramucirumab/pembrolizumab combination.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x